Merck-Eisai's cancer drug combo meets one main goal in late-stage study
28/10/2025 10:40
Oct 28 (Reuters) - Merck MRK.N and Eisai's 4523.T experimental combination treatment for a type of kidney cancer met one of the main goals in a late-stage study, the drugmakers said on Tuesday. (Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China